| Literature DB >> 26659380 |
Shuji Fukuda1, Shinsuke Nakagawa2, Rie Tatsumi3, Yoichi Morofuji1, Tomonori Takeshita1, Kentaro Hayashi1, Kunihiko Tanaka4, Takayuki Matsuo1, Masami Niwa5.
Abstract
The objective of the present study was to determine the effects of glucagon-like peptide-1 (GLP-1) on barrier functions and to assess the underlying mechanism using an in vitro blood-brain barrier (BBB) model comprised of a primary culture of rat brain capillary endothelial cells (RBECs). GLP-1 increased transendothelial electrical resistance and decreased the permeability of sodium fluorescein in RBECs in a dose- and time-dependent manner. The effects on these barrier functions were significantly reduced in the presence of the GLP-1 receptor antagonist exendin-3 (9-39) and the protein kinase A (PKA) inhibitor H-89. Western blot analysis showed that GLP-1 increased the amount of occludin and claudin-5. GLP-1 analogs are approved for treatment of type 2 diabetes mellitus, and thus, we examined the effects of GLP-1 on hyperglycemia-induced BBB damage. GLP-1 inhibited the increase in production of reactive oxygen species under hyperglycemia conditions and improved the BBB integrity induced by hyperglycemia. As GLP-1 stabilized the integrity of the BBB, probably via cAMP/PKA signaling, the possibility that GLP-1 acts as a BBB-protective drug should be considered.Entities:
Keywords: Blood-brain barrier; Glucagon-like peptide 1; Hyperglycemia; Tight junctions; cAMP/PKA signaling
Mesh:
Substances:
Year: 2015 PMID: 26659380 DOI: 10.1007/s12031-015-0696-1
Source DB: PubMed Journal: J Mol Neurosci ISSN: 0895-8696 Impact factor: 3.444